ARNA ARNA

Arena Pharmaceuticals Stock Price

99.99
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
99.99
Volume 0
Bid Price 99.00
Ask Price 99.99
News -
Day High

Low
45.50

52 Week Range

High
100.00

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Arena Pharmaceuticals Inc ARNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 99.99 20:00:00
Open Price Low Price High Price Close Price Prev Close
99.99 99.99
Trades Volume Avg Volume 52 Week Range
0 0 - 45.50 - 100.00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 99.99 USD

Period:

Draw Mode:

Arena Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.17B 61.66M 61.55M $ 54.00k $ - -10.12 -9.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 193.16k 4.70%

more financials information »

Arena Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months94.00100.0093.53598.634,000,3275.996.37%
6 Months57.73100.0048.1291.011,703,69042.2673.2%
1 Year62.06100.0045.5080.47917,04837.9361.12%
3 Years53.70100.0032.9568.82649,90446.2986.2%
5 Years13.40100.0012.2053.50694,61086.59646.19%

Arena Pharmaceuticals Description

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.


Your Recent History
NASDAQ
ARNA
Arena Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.